Core Viewpoint - The stock of TEBIO has experienced a decline of 8.58% since the beginning of the year, with significant trading activity noted on January 15, 2025, where the stock price reached 76.50 CNY per share, reflecting a market capitalization of 31.23 billion CNY [1] Group 1: Stock Performance - On January 15, 2025, TEBIO's stock rose by 2.08%, with a trading volume of 1.11 billion CNY and a turnover rate of 0.36% [1] - The stock has seen a decline of 6.79% over the last five trading days, 8.16% over the last twenty days, and 2.61% over the last sixty days [1] Group 2: Financial Performance - For the period from January to September 2025, TEBIO reported a revenue of 2.48 billion CNY, representing a year-on-year growth of 26.85%, and a net profit attributable to shareholders of 666 million CNY, which is a 20.21% increase year-on-year [2] - Since its A-share listing, TEBIO has distributed a total of 577 million CNY in dividends, with 506 million CNY distributed over the past three years [2] Group 3: Shareholder Information - As of September 30, 2025, TEBIO had 8,608 shareholders, an increase of 2.00% from the previous period, with an average of 47,258 circulating shares per shareholder, a decrease of 1.96% [2] - The top ten circulating shareholders include notable ETFs, with E Fund's SSE STAR 50 ETF holding 5.88 million shares, down by 856,700 shares from the previous period, and Huaxia's SSE STAR 50 Component ETF holding 5.73 million shares, down by 3.22 million shares [2]

Group 1 - The core point of the news is that TEBIO has experienced a continuous decline in stock price, dropping 2.14% on January 14, with a total market value of 30.59 billion yuan and a cumulative decline of 11.1% over five days [1] - TEBIO specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with its main business revenue composition being 86.85% from antiviral drugs, 12.87% from blood/tumor drugs, and 0.27% from other supplementary products [1] Group 2 - From the perspective of TEBIO's top ten circulating shareholders, E Fund's ETF has reduced its holdings by 856,700 shares, now holding 5.881 million shares, which is 1.45% of the circulating shares, resulting in a floating loss of approximately 9.64 million yuan today [2] - The E Fund's ETF has a total scale of 76.76 billion yuan, with a year-to-date return of 9.33% and a one-year return of 55.09% [2] - The fund managers, Lin Weibin and Cheng Xi, have significant experience, with Lin managing assets totaling 122.69 billion yuan and achieving a best return of 80.47% during his tenure [2]

Group 1 - The core point of the news is that TEBIO has experienced a decline in stock price, falling 0.49% to 76.58 CNY per share, with a total market capitalization of 31.259 billion CNY and a cumulative drop of 9.16% over the last four days [1] - TEBIO, established on August 7, 1996, is located in Xiamen, Fujian Province, and specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with 86.85% of its revenue coming from antiviral drugs, 12.87% from blood/cancer drugs, and 0.27% from other sources [1] Group 2 - From the perspective of fund holdings, Huashang Fund has a significant position in TEBIO, with its Huashang Innovation Medical Mixed A fund holding 26,700 shares, unchanged from the previous period, representing 4.31% of the fund's net value [2] - The Huashang Innovation Medical Mixed A fund, established on June 13, 2023, has a current size of 31.7429 million CNY, with a year-to-date return of 25.18% and a one-year return of 23.02%, ranking 3412 out of 8179 and 3511 out of 8148 respectively [2]

Group 1 - The core point of the news is that TeBao Bio experienced a 5.2% decline in stock price, reaching 76.40 yuan per share, with a trading volume of 251 million yuan and a turnover rate of 0.79%, resulting in a total market capitalization of 31.186 billion yuan [1] - TeBao Bio, established on August 7, 1996, is located in Xiamen, Fujian Province, and was listed on January 17, 2020. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs [1] - The main revenue composition of TeBao Bio includes 86.85% from antiviral drugs, 12.87% from blood/tumor drugs, and 0.27% from other supplementary products [1] Group 2 - From the perspective of fund holdings, HSBC Jintrust Fund has one fund heavily invested in TeBao Bio. The HSBC Jintrust Medical Pioneer Mixed A Fund (012358) reduced its holdings by 63,200 shares in the third quarter, now holding 160,200 shares, which accounts for 3.96% of the fund's net value, ranking as the ninth largest holding [2] - The HSBC Jintrust Medical Pioneer Mixed A Fund (012358) was established on July 12, 2021, with a current size of 170 million yuan. Year-to-date returns are 12.33%, ranking 269 out of 9,012 in its category; the one-year return is 86.56%, ranking 323 out of 8,157; and since inception, it has a loss of 15.62% [2] - The fund manager of HSBC Jintrust Medical Pioneer Mixed A Fund is Li Bokan, who has been in the position for 1 year and 13 days, with total assets under management of 340 million yuan. The best fund return during his tenure is 76.34%, while the worst is 75.58% [2]

Group 1 - The core point of the news is that TeBao Bio's stock price has decreased by 1.08%, currently trading at 82.71 yuan per share, with a total market capitalization of 33.76 billion yuan [1] - TeBao Bio, established on August 7, 1996, and listed on January 17, 2020, is primarily engaged in the research, production, and sales of recombinant proteins and long-acting modified drugs [1] - The company's main business revenue composition includes antiviral drugs at 86.85%, blood/cancer drugs at 12.87%, and other (supplementary) at 0.27% [1] Group 2 - From the perspective of fund holdings, Jin Yuan Shun An Fund has one fund heavily invested in TeBao Bio, specifically the Jin Yuan Shun An Value Growth Mixed Fund (620004), which held 16,400 shares, accounting for 1.97% of the fund's net value [2] - The Jin Yuan Shun An Value Growth Mixed Fund has a current scale of 70.05 million yuan, with a year-to-date return of 19.37% and a one-year return of 17.03% [2] - The fund manager, Kong Xiangpeng, has been in position for 8 years and 189 days, while Han Chenyang has been in position for 2 years and 307 days, with respective best and worst fund returns during their tenure [2]

Core Viewpoint - The stock of TEBIO has shown fluctuations with a recent increase of 2.03%, reflecting a total market capitalization of 30.406 billion yuan and a trading volume of 116 million yuan as of November 3 [1]. Financial Performance - For the period from January to September 2025, TEBIO reported a revenue of 2.48 billion yuan, representing a year-on-year growth of 26.85%. The net profit attributable to shareholders was 666 million yuan, showing a year-on-year increase of 20.21% [2]. - Cumulatively, TEBIO has distributed a total of 577 million yuan in dividends since its A-share listing, with 506 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, TEBIO had 8,608 shareholders, an increase of 2% from the previous period. The average number of circulating shares per shareholder decreased by 1.96% to 47,258 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by E Fund's SSE STAR 50 ETF and Huaxia's SSE STAR 50 Component ETF, with reductions of 856,700 shares and 3,216,200 shares respectively [3]. Stock Performance - TEBIO's stock price has increased by 2.39% year-to-date, with a 4.92% rise over the last five trading days. However, it has experienced a decline of 9.19% over the past 20 days and 17.90% over the last 60 days [1].

Core Viewpoint - The stock of TEBIO has shown a slight increase of 2.03% on October 29, with a current price of 72.45 CNY per share, despite a year-to-date decline of 0.41% and a more significant drop of 6.29% over the past five trading days [1] Financial Performance - For the period from January to September 2025, TEBIO achieved a revenue of 2.48 billion CNY, representing a year-on-year growth of 26.85%. The net profit attributable to shareholders was 666 million CNY, reflecting a growth of 20.21% compared to the previous year [2] Shareholder Information - As of September 30, 2025, TEBIO had 8,608 shareholders, an increase of 2% from the previous period. The average number of circulating shares per shareholder decreased by 1.96% to 47,258 shares [2] Dividend Distribution - TEBIO has distributed a total of 577 million CNY in dividends since its A-share listing, with 506 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the seventh-largest circulating shareholder is E Fund's SSE STAR 50 ETF, holding 5.88 million shares, a decrease of 856,700 shares from the previous period. The eighth-largest shareholder is Huaxia's SSE STAR 50 Component ETF, holding 5.73 million shares, down by 3.22 million shares [3]

Core Viewpoint - The stock of TEBIO has experienced a decline, with a current price of 71.16 CNY per share, reflecting a year-to-date drop of 2.19% and a significant decrease over the past five trading days of 8.36% [1] Financial Performance - For the period from January to September 2025, TEBIO reported a revenue of 2.48 billion CNY, representing a year-on-year growth of 26.85%. The net profit attributable to shareholders was 666 million CNY, showing a year-on-year increase of 20.21% [2] Shareholder Information - As of September 30, 2025, TEBIO had 8,608 shareholders, an increase of 2% from the previous period. The average number of circulating shares per shareholder decreased by 1.96% to 47,258 shares [2] Dividend Distribution - TEBIO has distributed a total of 577 million CNY in dividends since its A-share listing, with 506 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the seventh-largest circulating shareholder is E Fund's SSE STAR 50 ETF, holding 5.88 million shares, a decrease of 856,700 shares from the previous period. The eighth-largest shareholder is Huaxia's SSE STAR 50 Component ETF, holding 5.73 million shares, down by 3.22 million shares [3]

Core Viewpoint - The stock price of TEBIO has been declining for four consecutive days, with a total drop of 7.44% during this period, indicating potential concerns among investors [1]. Company Overview - TEBIO, officially known as Xiamen TEBIO Engineering Co., Ltd., was established on August 7, 1996, and went public on January 17, 2020. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs [1]. - The main revenue composition of TEBIO includes antiviral drugs (86.85%), blood/cancer drugs (12.87%), and other supplementary products (0.27%) [1]. Fund Holdings - Huatai-PB Fund has a significant holding in TEBIO, with its Huatai-PB Quantitative Chuangying Mixed A Fund (010303) holding 15,400 shares, unchanged from the previous period, accounting for 1.34% of the fund's net value [2]. - The fund has experienced a floating loss of approximately 18,500 yuan today, with a total floating loss of 96,100 yuan during the four-day decline [2]. - The Huatai-PB Quantitative Chuangying Mixed A Fund was established on November 12, 2020, with a current scale of 58.35 million yuan and has achieved a year-to-date return of 43.46% [2].

Core Viewpoint - The stock of TEBIO experienced a decline of 2.06% on October 16, 2023, with a trading volume of 1.40 billion yuan and a market capitalization of 31.974 billion yuan [1] Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion yuan, representing a year-on-year growth of 26.96%, and a net profit attributable to shareholders of 428 million yuan, which is a 40.60% increase compared to the previous year [2] Shareholder and Market Activity - As of June 30, 2025, TEBIO had 8,439 shareholders, an increase of 13.00% from the previous period, with an average of 48,204 circulating shares per shareholder, down by 11.51% [2] - The stock's performance shows an 8.04% increase year-to-date, but a decline of 3.44% over the last five trading days and 3.99% over the last twenty days [1] Dividend Distribution - TEBIO has distributed a total of 577 million yuan in dividends since its A-share listing, with 506 million yuan distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included the Huaxia SSE STAR 50 ETF, which increased its holdings by 837,500 shares, and the E Fund SSE STAR 50 ETF, which added 189,900 shares [3]